Title:
Efficacy and tolerability of bromelain in patients with chronic rhinosinusitis a pilot study
Authors:
L. Büttner, N. Achilles, M. Böhm, K. Shah-Hosseini and R. Mösges
Institutions:
Institute of Medical Statistics, Informatics and Epidemiology, University of Cologne, Germany
Keywords:
Chronic rhinosinusitis, nasal polyp, bromelain, quality of life, treatment outcome
Pages:
217 - 225
Abstract:
Efficacy and tolerability of bromelain in patients with chronic rhinosinusitis a pilot study. Objectives: To evaluate the efficacy, tolerability, and impact on quality of life (QoL) of bromelain tablets (500 FIP) in patients with chronic rhinosinusitis (CRS). Methods: In this prospective, open­label observational pilot study, 12 patients suffering from CRS with (CRS+NP) or without (CRS­NP) nasal polyps who had undergone prior sinus surgery were treated with bromelain tablets (500 FIP) for three months. Efficacy was evaluated using symptom scores (Total Symptom Scores: TSS); a Total Rhinoscopy Score (TRS) was also determined. QoL was assessed by using the German, adapted version of the Sinonasal Outcome Test 20 (SNOT­20 GAV). Results: Treatment with bromelain tablets (500 FIP) improved TSS, TRS and SNOT­20 GAV on average. This treatment was found to be more effective, however, for CRS­NP than for CRS+NP. The average intake was six tablets, equivalent to a daily dosage of 3000 FIP. No adverse events were observed. Conclusion: Preliminary results indicate good tolerability, symptom control, and improvement in QoL for the treatment of CRS using bromelain tablets (500 FIP).
Issue:
Vol. 9, 2013, 3rd trimester


Download:
Efficacy and tolerability of bromelain in patients with chronic rhinosinusitis a pilot study